At the news
? NEUTRALIMPACT 5/10 CLUSTER filed Feb 26, 2026 at 19:00 ET
United Therapeutics CEO Martine Rothblatt and several insiders engaged in a series of derivative exercises and open-market sales over a 3-day period, including $1.39M in open-market share sales by Rothblatt and $2.8M in derivative exercises at non-zero cost. The activity is part of a structured transaction plan, not opportunistic selling.
- CEO Martine Rothblatt sold 9,779 shares in open market for $1.52M across two transactions on March 3 and March 5, 2026.
- Rothblatt exercised 38,000 derivative securities in total, with $2.77M of those exercises at $146.03 per share (cash-out or cashless exercise).
- Other insiders (EVP, directors) exercised derivatives totaling $1.92M in value at non-zero cost, with additional non-cash exercises (tax withholding or awards).
- Total open-market sales in cluster: $1.55M (Rothblatt $1.52M, Malcolm Jan $25,460).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access